Clinical comprehensive evaluation of three oral Janus kinase inhibitors for atopic dermatitis

YIN Kerui; WU Ziyang; WANG Wanqing; HANG Yongfu; WANG Zihan; ZHANG Jingjing; ZHU Jianguo

doi:10.6039/j.issn.1001-0408.2024.12.02

您当前的位置：

首页 >

文章列表页 >

Clinical comprehensive evaluation of three oral Janus kinase inhibitors for atopic dermatitis

更新时间：2025-09-26

- Clinical comprehensive evaluation of three oral Janus kinase inhibitors for atopic dermatitis
- ZHONGGUO YAOFANG Vol. 35, Issue 12, Pages: 1419-1425(2024)
- 作者机构：
  
  1.苏州大学附属第一医院药学部，江苏苏州　215006
  2.苏州大学药学院，江苏苏州　215021
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.12.02
  CLC： R969;R986
- Received：27 December 2023，
  
  Revised：2024-02-09，
  
  Accepted：09 April 2024，
  
  Published：30 June 2024
- 稿件说明：
移动端阅览
殷科蕊,吴紫阳,汪皖青,等.3种口服Janus激酶抑制剂治疗特应性皮炎的临床综合评价[J].中国药房,2024,35(12):1419-1425.

YIN Kerui,WU Ziyang,WANG Wanqing,et al.Clinical comprehensive evaluation of three oral Janus kinase inhibitors for atopic dermatitis[J].ZHONGGUO YAOFANG,2024,35(12):1419-1425.
殷科蕊,吴紫阳,汪皖青,等.3种口服Janus激酶抑制剂治疗特应性皮炎的临床综合评价[J].中国药房,2024,35(12):1419-1425. DOI： 10.6039/j.issn.1001-0408.2024.12.02.

YIN Kerui,WU Ziyang,WANG Wanqing,et al.Clinical comprehensive evaluation of three oral Janus kinase inhibitors for atopic dermatitis[J].ZHONGGUO YAOFANG,2024,35(12):1419-1425. DOI： 10.6039/j.issn.1001-0408.2024.12.02.

摘要

目的

对乌帕替尼、阿布昔替尼和巴瑞替尼3种口服Janus激酶抑制剂（JAKi）治疗特应性皮炎进行临床综合评价。

方法

从安全性、有效性、经济性、适宜性、可及性、创新性6个维度进行评价。使用Meta分析评价3种口服JAKi的安全性和有效性；检索国内外药物经济学研究并计算各JAKi治疗费用以评价经济性；结合文献和药品说明书等评价适宜性；使用问卷调查评价3种口服JAKi的可及性；从JAKi的作用机制角度阐述其创新性。

结果

安全性方面，乌帕替尼30 mg组上呼吸道感染发生率[OR＝1.47，95%CI（1.04，2.08），

＝0.03

]

和鼻咽炎发生率[OR＝1.44，95%CI（1.06，1.95），

＝0.02

]

显著高于安慰剂组；巴瑞替尼4 mg组的鼻咽炎发生率显著高于安慰剂组[OR＝2.24，95%CI（1.39，3.61），

＝0.000 8

]

和巴瑞替尼2 mg组[OR＝0.48，95%CI（0.31，0.74），

＝0.001

]

。有效性方面，3种口服JAKi无论剂量如何，有效性均显著优于安慰剂组，且乌帕替尼和阿布昔替尼的有效性呈剂量依赖性（

＜0.000 1）。经济性方面，巴瑞替尼的年治疗费用最低（13 870.0元），但其在我国没有获批AD适应证；其次为乌帕替尼（27 192.5元）。3种JAKi的总体适宜性较好，但均不适用于重度肝损伤患者。巴瑞替尼的可获得率最高（59.4%），但在我国医保体系下乌帕替尼的可负担性较好。3种JAKi中，乌帕替尼与阿布昔替尼的创新性更优。

结论

3种口服JAKi治疗特应性皮炎的安全性可控，有效性良好；考虑到医保报销问题，建议我国患者优先使用乌帕替尼。

Abstract

OBJECTIVE

To comprehensively evaluate the three oral Janus kinase inhibitors （JAKi） such as upadacitinib， abrocitinib and baricitinib in the treatment of atopic dermatitis.

METHODS

The six dimensions of safety， efficacy， economy， appropriateness， accessibility and innovativeness were used for evaluation. Meta-analysis was conducted to evaluate the safety and efficacy of three oral JAKi； pharmacoeconomic studies were searched， and the treatment costs were calculated to evaluate the economy of each JAKi. Appropriateness was described based on literature review and drug labels. Accessibility of three oral JAKi was assessed by using a questionnaire survey. The innovation of JAKi was elucidated from the perspective of its mechanism of action.

RESULTS

In terms of safety， the incidence of upper respiratory tract infection （OR＝1.47， 95%CI of 1.04-2.08，

＝0.03） and nasopharyngitis （OR＝1.44，

95%CI of 1.06-1.95，

＝0.02） in the upadacitinib 30 mg group was significantly higher than that in the placebo group； the incidence of nasopharyngitis in baricitinib 4 mg group was significantly higher than that in the placebo group （OR＝2.24， 95%CI of 1.39-3.61，

＝0.000 8） and baricitinib 2 mg group （OR＝0.48， 95%CI of 0.31-0.74，

＝0.001）. In terms of efficacy， regardless of the dosage， all three JAKi groups were superior to the placebo group， and the high-dose groups of upadacitinib and abrocitinib were superior to the low-dose groups （

＜0.000 1）. In terms of economy， the annual treatment cost of baricitinib was the lowest （13 870.0 yuan）， but it has not been approved for atopic dermatitis indication in China； next was upadacitinib （27 192.5 yuan）. In terms of appropriateness， the overall appropriateness of the three JAKis was good， but none of them was suitable for patients with severe liver injury. In terms of accessibility， baricitinib had the highest availability rate （59.4%）， but the affordability of upadacitinib was relatively good under China’s medical insurance system. In terms of innovation， among the three types of JAKi， upadacitinib and abrocitinib had better innovation.

CONCLUSIONS

Three oral JAKi treatments for atopic dermatitis have controllable safety and good efficacy. Considering the issue of medical insurance reimbursement， it is recommended that Chinese patients use upadacitinib.

关键词

Keywords

references

BAKKER D ， DE BRUIN-WELLER M ， DRYLEWICZ J ， et al . Biomarkers in atopic dermatitis [J ] . J Allergy Clin Immunol ， 2023 ， 151 （ 5 ）： 1163 - 1168 .

GU C Y ， YAO X ， LI W . Burden of disease：the current status of the diagnosis and management of atopic dermatitis in China [J ] . J Clin Med ， 2023 ， 12 （ 16 ）： 5370 .

DONG W L ， AN J ， YU M ， et al . The prevalence and year lived with disability of atopic dermatitis in China：findings from the global burden of disease study 2019 [J ] . World Allergy Organ J ， 2021 ， 14 （ 11 ）： 100604 .

EZEONWUMELU I J ， GARCIA-VIDAL E ， BALLANA E . JAK-STAT pathway：a novel target to tackle viral infections [J ] . Viruses ， 2021 ， 13 （ 12 ）： 2379 .

SCHULER C F 4th ， BILLI A C ， MAVERAKIS E ， et al . Novel insights into atopic dermatitis [J ] . J Allergy Clin Immunol ， 2023 ， 151 （ 5 ）： 1145 - 1154 .

BIEBER T ， THYSSEN J P ， REICH K ， et al . Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials [J ] . J Eur Acad Dermatol Venereol ， 2021 ， 35 （ 2 ）： 476 - 485 .

WAN H Y ， JIA H P ， XIA T ， et al . Comparative efficacy and safety of abrocitinib，baricitinib，and upadacitinib for moderate-to-severe atopic dermatitis：a network meta-analysis [J ] . Dermatol Ther ， 2022 ， 35 （ 9 ）： e15636 .

HIGGINS J ， THOMAS J ， CHANDLER J ， et al . Cochrane handbook for systematic reviews of interventions version 6.4 [EB/OL ] .（ 2023-08-22 ）[ 2023-10-18 ] . https：//training.cochrane.org/handbook https://training.cochrane.org/handbook .

GUTTMAN-YASSKY E ， THAÇI D ， PANGAN A L ， et al . Upadacitinib in adults with moderate to severe atopic dermatitis：16-week results from a randomized，placebo-controlled trial [J ] . J Allergy Clin Immunol ， 2020 ， 145 （ 3 ）： 877 - 884 .

GUTTMAN-YASSKY E ， TEIXEIRA H D ， SIMPSON E L ， et al . Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis（measure Up 1 and measure Up 2）：results from two rep-licate double-blind，randomised controlled phase 3 trials [J ] . Lancet ， 2021 ， 397 （ 10290 ）： 2151 - 2168 .

REICH K ， TEIXEIRA H D ， BRUIN-WELLER M D ， et al . Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis（AD Up）：results from a randomised，double-blind，placebo-controlled，phase 3 trial [J ] . Lancet ， 2021 ， 397 （ 10290 ）： 2169 - 2181 .

KATOH N ， OHYA Y ， MUROTA H ， et al . A phase 3 randomized，multicenter，double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan（rising Up）：an interim 24-week analysis [J ] . JAAD Int ， 2022 ， 6 ： 27 - 36 .

GOODERHAM M J ， FORMAN S B ， BISSONNETTE R ， et al . Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis：a phase 2 randomized clinical trial [J ] . JAMA Dermatol ， 2019 ， 155 （ 12 ）： 1371 - 1379 .

SIMPSON E L ， SINCLAIR R ， FORMAN S ， et al . Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis（JADE MONO-1）：a multicentre，double-blind，randomised，placebo-controlled，phase 3 trial [J ] . Lancet ， 2020 ， 396 （ 10246 ）： 255 - 266 .

SILVERBERG J I ， SIMPSON E L ， THYSSEN J P ， et al . Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis：a randomized clinical trial [J ] . JAMA Dermatol ， 2020 ， 156 （ 8 ）： 863 - 873 .

BIEBER T ， SIMPSON E L ， SILVERBERG J I ， et al . Abrocitinib versus placebo or dupilumab for atopic dermatitis [J ] . N Engl J Med ， 2021 ， 384 （ 12 ）： 1101 - 1112 .

GUTTMAN-YASSKY E ， SILVERBERG J I ， NEMOTO O ， et al . Baricitinib in adult patients with moderate-to-severe atopic dermatitis：a phase 2 parallel，double-blinded，randomized placebo-controlled multiple-dose study [J ] . J Am Acad Dermatol ， 2019 ， 80 （ 4 ）： 913 - 921.e9 .

REICH K ， KABASHIMA K ， PERIS K ， et al . Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis：a randomized clinical trial [J ] . JAMA Dermatol ， 2020 ， 156 （ 12 ）： 1333 - 1343 .

SIMPSON E L ， LACOUR J P ， SPELMAN L ， et al . Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids：results from two randomized monotherapy phase Ⅲ trials [J ] . Br J Dermatol ， 2020 ， 183 （ 2 ）： 242 - 255 .

BIEBER T ， REICH K ， PAUL C ， et al . Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response，intolerance or contraindication to ciclosporin：results from a randomized，placebo-controlled，phase Ⅲ clinical trial（BREEZE-AD4） [J ] . Br J Dermatol ， 2022 ， 187 （ 3 ）： 338 - 352 .

ROMERO JIMÉNEZ R M ， HERRANZ PINTO P ， CAMPOS DOMÍNGUEZ M ， et al . Cost-effectiveness analysis of abrocitinib compared with other systemic treatments for severe atopic dermatitis in Spain [J ] . Pharmacoecon Open ， 2024 ， 8 （ 2 ）： 291 - 302 .

中华医学会皮肤性病学分会免疫学组，特应性皮炎协作研究中心 . 中国特应性皮炎诊疗指南： 2020版 [J ] . 中华皮肤科杂志， 2020 ， 53 （ 2 ）： 81 - 88 .

Immunology Group of the Dermatology and Venereology Branch of the Chinese Medical Association ， Collaborative Research Center for Atopic Dermatitis . Chinese guideline for diagnosis and treatment of atopic dermatitis：2020 edition [J ] . Chin J Dermatol ， 2020 ， 53 （ 2 ）： 81 - 88 .

RADI G ， SIMONETTI O ， RIZZETTO G ， et al . Baricitinib：the first JAK inhibitor approved in Europe for the treatment of moderate to severe atopic dermatitis in adult patients [J ] . Healthcare ， 2021 ， 9 （ 11 ）： 1575 .

MOHAMED M E F ， TRUEMAN S ， FENG T ， et al . Cha-racterization of the effect of renal impairment on upadacitinib pharmacokinetics [J ] . J Clin Pharmacol ， 2019 ， 59 （ 6 ）： 856 - 862 .

TRUEMAN S ， MOHAMED M F ， FENG T ， et al . Characterization of the effect of hepatic impairment on upadacitinib pharmacokinetics [J ] . J Clin Pharmacol ， 2019 ， 59 （ 9 ）： 1188 - 1194 .

WANG E Q ， LE V ， O’GORMAN M ， et al . Effects of hepatic impairment on the pharmacokinetics of abrocitinib and its metabolites [J ] . J Clin Pharmacol ， 2021 ， 61 （ 10 ）： 1311 - 1323 .

WANG E Q ， LE V ， WINTON J A ， et al . Effects of renal impairment on the pharmacokinetics of abrocitinib and its metabolites [J ] . J Clin Pharmacol ， 2022 ， 62 （ 4 ）： 505 - 519 .

HOY S M . Baricitinib：a review in moderate to severe atopic dermatitis [J ] . Am J Clin Dermatol ， 2022 ， 23 （ 3 ）： 409 - 420 .

SHAWKY A M ， ALMALKI F A ， ABDALLA A N ， et al . A comprehensive overview of globally approved JAK inhibitors [J ] . Pharmaceutics ， 2022 ， 14 （ 5 ）： 1001 .

SZALUS K ， TRZECIAK M ， NOWICKI R J . JAK-STAT inhibitors in atopic dermatitis from pathogenesis to clinical trials results [J ] . Microorganisms ， 2020 ， 8 （ 11 ）： 1743 .

DAVIS D M R ， DRUCKER A M ， ALIKHAN A ， et al . Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies [J ] . J Am Acad Dermatol ， 2024 ， 90 （ 2 ）： e43 - e56 .

National Institute for Health and Care Excellence . Baricitinib for treating moderate to severe atopic dermatitis [EB/OL ] .（ 2021-03-03 ）[ 2023-10-18 ] . www.nice.org.uk/gui-dance/ta681 www.nice.org.uk/gui-dance/ta681 .

National Institute for Health and Care Excellence . Abrocitinib，tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis [EB/OL ] .（ 2022-08-03 ）[ 2023-10-18 ] . www.nice.org.uk/guidance/ta8141 www.nice.org.uk/guidance/ta8141 .

Views

230

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰